Denosumab for bone diseases: translating bone biology into targeted therapy
نویسندگان
چکیده
منابع مشابه
Denosumab for the treatment of joint and bone diseases
Rheumatoid arthritis (RA) is a representative inflammatory disease characterized with systemic, chronic and destructive synovitis and subsequent bone destruction that causes severe disability and mortality. Since joint destruction occurs from the early disease, its diagnosis and treatment have to be done timely. The combinational use of methotrexate and biologics targeting TNF and IL-6 has revo...
متن کاملDenosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
CASE A 68-year-old female was diagnosed with giant cell tumor of bone (GCTB) metastatic to her lungs. The patient was treated with IV denosumab for the course of 4.5 years for these metastases. The metastatic tumor burden decreased significantly after only 3 months of therapy. The size of the metastases has been stable for over 4 years. CONCLUSION Denosumab therapy has promise in the treatmen...
متن کاملBone Sarcomas: From Biology to Targeted Therapies
Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour volume for Ewing sarcomas not operated), patients with multiple metastases at or those who relap...
متن کاملDenosumab, cortical bone and bone erosions in rheumatoid arthritis.
Takeuchi et al demonstrate an additional inhibitory effect on the progression of bone erosions in rheumatoid arthritis (RA) with the addition to methotrexate of an anti-receptor activator of nuclear factor kappa-B ligand (RANKL) antibody, denosumab, confirming results already reported 8 years ago by Cohen and colleagues. Insufficient inhibition of structural joint damage by diseasemodifying ant...
متن کاملBone-targeted therapy in prostate cancer
Androgen deprivation therapy (ADT) is standard for advanced prostate cancer and is now increasingly used as adjunct therapy in high-risk or locally advanced disease and for the treatment of recurring disease based on rising prostate-specific antigen levels. Testosterone stimulates bone formation directly by stimulating the osteoblast proliferation, inhibiting the apoptosis of both osteoblasts a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Endocrinology
سال: 2011
ISSN: 0804-4643,1479-683X
DOI: 10.1530/eje-11-0454